序贯膀胱内灌注吉西他滨和多西他赛与卡介苗治疗卡介苗无反应性非肌层浸润性膀胱癌患者的肿瘤学结局比较
本研究基于十家学术机构的数据,比较了序贯膀胱内灌注吉西他滨和多西他赛(gem/doce)与再次卡介苗(BCG)治疗在卡介苗无反应性非肌层浸润性膀胱癌(NMIBC)患者中的肿瘤学结局。共纳入299例患者,其中204例接受再次BCG治疗,95例接受gem/doce治疗。结果显示,gem/doce组在无进展生存(PFS)、无膀胱切除术生存(CFS)和肿瘤特异性生存(CSS)方面均优于再次BCG组,而高级别无复发生存(HGRFS)、无转移生存(MFS)和总生存(OS)两组相似。
要点
- 在卡介苗无反应性NMIBC患者中,gem/doce组较再次BCG组的无进展生存更高(HR 2.6)。
- gem/doce组的无膀胱切除术生存(HR 2.0)和肿瘤特异性生存(HR 3.7)也高于再次BCG组。
- 两组的高级别无复发生存、无转移生存和总生存相似。
核心结论
- 研究结果表明,在拒绝或不适合行膀胱切除术的卡介苗无反应性NMIBC患者中,膀胱内灌注gem/doce与较低的进展率相关(相比再次BCG)。
研究设计与样本
- 研究收集了十家学术机构中根据美国食品药品监督管理局(FDA)指南定义为卡介苗无反应性NMIBC患者的数据。
- 共299例患者,其中204例在卡介苗无反应时接受再次BCG治疗,95例接受gem/doce治疗。
- 采用Kaplan-Meier法和Cox比例风险比(HR)比较两组肿瘤学结局的差异。
主要发现
- gem/doce组的无进展生存高于再次BCG组(HR 2.6,95%CI 1.1-5.0,p=0.03)。
- gem/doce组的无膀胱切除术生存高于再次BCG组(HR 2.0,95%CI 1.2-3.4,p=0.01)。
- gem/doce组的肿瘤特异性生存高于再次BCG组(HR 3.7,95%CI 1.1-12.3,p=0.03)。
- 两组的高级别无复发生存、无转移生存和总生存相似。
临床怎么用
- 作者认为,对于拒绝或不适合行膀胱切除术的卡介苗无反应性NMIBC患者,膀胱内灌注gem/doce与较低的进展率相关(相比再次BCG)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Non-muscle-invasive bladder cancer (NMIBC) patients treated with additional bacillus Calmette-Guérin (BCG) may become unresponsive to BCG. Recently, sequential intravesical gemcitabine and docetaxel (gem/doce) are being used for NMIBC. This study aims to compare oncologic outcomes between sequential intravesical gem/doce versus additional BCG in patients with BCG-unresponsive NMIBC. METHODS: Data were collected from ten academic institutions on patients with BCG-unresponsive NMIBC based on the Food and Drug Administration guidelines. Information on high-grade recurrence-free (HGRFS), progression-free (PFS), cystectomy-free (CFS), metastasis-free (MFS), cancer-specific (CSS), and overall (OS) survival was collected. The Kaplan-Meier method and Cox proportional hazard ratios (HRs) were used to determine differences in oncologic outcomes between the Gem/Doce and BCG groups. KEY FINDINGS AND LIMITATIONS: Of 299 total patients, 204 underwent additional BCG treatment at the time of BCG unresponsiveness and 95 underwent gem/doce treatment. Rates of PFS (HR 2.6, 95% confidence interval [CI] 1.1-5.0, p = 0.03), CFS (HR 2.0, 95% CI 1.2-3.4, p = 0.01), and CSS (HR 3.7, 95% CI 1.1-12.3, p=0.03) were higher in patients receiving gem/doce. HGRFS, MFS, and OS were similar between both groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: The findings from this study suggest that intravesical gem/doce is associated with lower rates of progression than additional BCG in patients with BCG-unresponsive NMIBC who decline or are ineligible for cystectomy. PATIENT SUMMARY: In this report, we looked at outcomes between patients with noninvasive bladder cancer who were treated with additional bacillus Calmette-Guérin (BCG) or gemcitabine-docetaxel combination after not responding to primary BCG therapy. We found that intravesical gemcitabine-docetaxel was associated with fewer progression events than additional salvage BCG therapy.
引用
- Taylor J, Kamat AM, Annapureddy D, et al. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer. Eur Urol Oncol. 2024. PMID: 39694798. doi:10.1016/j.euo.2024.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。